Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Not passing GST...

    Not passing GST benefit to consumers: Abbott gets HC relief after Challenging powers of National Anti-Profiteering Authority

    Farhat NasimWritten by Farhat Nasim Published On 2019-05-09T14:11:22+05:30  |  Updated On 9 May 2019 2:11 PM IST
    Not passing GST benefit to consumers: Abbott gets HC relief after Challenging powers of National Anti-Profiteering Authority

    New Delhi: In an interim relief, the Delhi High Court has stayed proceedings against Abbott Healthcare which was found guilty by the National Anti-Profiteering Agency (NAPA) of charging higher Goods and Services Tax (GST) and not passing on the benefit of GST rate reduction to the tune of Rs 96.59 lakh to consumers.


    The move comes after the company questioned the constitutional validity of the provisions as well as the National Anti-Profiteering Agency's (NAPA's) powers to extend the probe to its other products.




    The National Anti-Profiteering Authority (NAA) has been constituted under Section 171 of the Central Goods and Services Tax Act, 2017 to ensure that the reduction in the rate of tax or the benefit of the input tax credit is passed on to the recipient by way of commensurate reduction in prices.


    A probe had been conducted by the National Anti-Profiteering Authority (NAPA) on the company post which it held company guilty of not passing the benefits.


    It was found that despite a fall in tax rates from 28% to 18%, the base price of the product of Abbott was increased from Rs 202.06 to Rs 230.90 per unit which resulted in an increase of the selling price and denial of passing the benefit of tax reduction to the customers.

    The authority had directed the Mumbai- based company to deposit the amount in the consumer welfare fund along with 18 per cent interest.


    Also Read: GUILTY: Abbott Healthcare did not pass Rs 96.59 lakh GST benefit to consumers


    Challenging the constitutional validity of the NAPA, Abbott's counsel recently appeared before the High Court bench of Justice S Muralidhar and I S Mehta.


    The company has argued that this was way beyond the powers given to the agency under Central GST rules.


    Abbott’s counsel Mukul Rohatagi stated that the company had accepted to pay the demand of Rs 96 lakh along with the applicable interest.


    However, Abbott has reportedly undertaken the same on condition that no further investigation and penalty by NAPA was conducted.


    Besides Abbott, Hindustan Unilever and Jubilant Foodworks, are other companies which have also questioned the constitutional validity, while challenging NAPA's orders.


    "The order gives an opportunity to all dealers against whom anti-profiteering proceedings are initiated to consider filing a letter with anti-profiteering authorities, pleading that their proceedings should be stayed, till the time the issue surrounding constitutional validity is settled by courts," Harpreet Singh, partner at consulting firm KPMG told TOI.

    Abbott healthcareAbbott melaglowanti profiteering authoritybase priceconstitutionconstitutional validityconsumercourt orderDelhiDelhi high courtdepigmentation creamGSTgst benefitshealthHindustan UnileverJubilant FoodworksKPMGmedicalmelaglowmelaglow richNAPAnational anti profiteering authoritytax reductionwelfare fund
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok